SEC Comment Letter 0000000000-23-012565 to TELA Bio, Inc. (TELA) (CIK 0001561921) (TELA)
TELA Bio, Inc. (TELA) (CIK 0001561921)
Date: Nov. 16, 2023 · CIK: 0001561921 · Accession: 0000000000-23-012565
AI Filing Summary & Sentiment
File numbers found in text: 333-275511
Letter
United States securities and exchange commission logo November 16, 2023 Antony Koblish President and Chief Executive Officer TELA Bio, Inc. 1 Great Valley Parkway, Suite 24 Malvern, Pennsylvania 19355 Re:TELA Bio, Inc. Registration Statement on Form S-3 Filed November 13, 2023 File No. 333-275511 Dear Antony Koblish: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Conlon Danberg at 202-551-4466 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Justin S. Platt, Esq.
Show Raw Text
United States securities and exchange commission logo
November 16, 2023
Antony Koblish
President and Chief Executive Officer
TELA Bio, Inc.
1 Great Valley Parkway, Suite 24
Malvern, Pennsylvania 19355
Re:TELA Bio, Inc.
Registration Statement on Form S-3
Filed November 13, 2023
File No. 333-275511
Dear Antony Koblish:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Conlon Danberg at 202-551-4466 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Justin S. Platt, Esq.